Symbiota Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
- Paid Up Capital ₹ 3.35 M
- Company Age 13 Year, 2 Months
- Last Filing with ROC 31 Mar 2021
- Revenue Growth %
- Profit Growth -586.15%
- Ebitda -118.08%
- Net Worth -1.86%
- Total Assets -3.00%
About Symbiota Pharmaceuticals
Symbiota Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 26 November 2011 and has a history of 13 years and two months. Its registered office is in Ranchi, Jharkhand.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 3.35 M, as per Ministry of Corporate Affairs (MCA) records.
Sudhir Kumar, Binay Kumar, Manish Kumar, and Two other members serve as directors at the Company.
Company Details
-
LocationRanchi, Jharkhand
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51397JH2011PTC000014
-
Company No.
000014
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
26 Nov 2011
-
Date of AGM
30 Nov 2021
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Unlisted
-
ROC Code
Roc Jharkhand
Industry
Who are the key members and board of directors at Symbiota Pharmaceuticals?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sudhir Kumar
|
Director | 15-Jan-2014 | Current |
|
Binay Kumar
|
Director | 26-Nov-2011 | Current |
|
Manish Kumar
|
Director | 10-Jul-2012 | Current |
|
Shailesh Kumar
|
Director | 15-Jan-2014 | Current |
|
Amit Kumar
|
Director | 26-Nov-2011 | Current |
Financial Performance of Symbiota Pharmaceuticals.
Symbiota Pharmaceuticals Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 586.15% decrease in profit. The company's net worth dipped by a decrease of 1.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Symbiota Pharmaceuticals?
In 2017, Symbiota Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Symbiota Pharmaceuticals?
Unlock and access historical data on people associated with Symbiota Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Symbiota Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Symbiota Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
